Aeglea Bio Therapeutics Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Aeglea Bio Therapeutics prevailing Real Value cannot be determined due to lack of data. The current price of Aeglea Bio Therapeutics is $0.0. Our model approximates the value of Aeglea Bio Therapeutics from analyzing the firm fundamentals such as operating margin of (94.85) %, and Return On Equity of -2.81 as well as examining its technical indicators and probability of bankruptcy.
Aeglea Bio Total Value Analysis
Aeglea Bio Therapeutics is presently expected to have valuation of 228.21 M with market capitalization of 45.59 M, debt of 4.63 M, and cash on hands of 73.68 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Aeglea Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
228.21 M | 45.59 M | 4.63 M | 73.68 M |
Aeglea Bio Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aeglea Bio Therapeutics recorded a loss per share of 74.15. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 8th of September 2023. Based on the analysis of Aeglea Bio's profitability, liquidity, and operating efficiency, Aeglea Bio Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Aeglea Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aeglea Bio has an asset utilization ratio of 3.27 percent. This indicates that the Company is making $0.0327 for each dollar of assets. An increasing asset utilization means that Aeglea Bio Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Aeglea Bio Ownership Allocation
The majority of Aeglea Bio Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aeglea Bio Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aeglea Bio. Please pay attention to any change in the institutional holdings of Aeglea Bio Therapeutics as this could imply that something significant has changed or is about to change at the company.Aeglea Bio Profitability Analysis
The company reported the previous year's revenue of 2.33 M. Net Loss for the year was (83.81 M) with loss before overhead, payroll, taxes, and interest of (262 K).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Aeglea Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Aeglea Bio and how it compares across the competition.
Aeglea Bio Growth Indicators
Investing in growth stocks can be very risky. If the company such as Aeglea Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 3.4 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |